Table 4.
Ongoing clinical trials with engineered NK cells
| Modification | Phase | Malignancy | Combination Treatments | Clinicaltrial.gov Designation |
|---|---|---|---|---|
| NKG2D ligand CAR | Phase I | R/R AML, R/R MDS | Monotherapy | NCT04623944 |
| HER2 CAR | Phase I | Glioblastoma | Monotherapy | NCT03383978 |
| 158V non-cleavable CD16 | Phase I | B cell lymphoma, AML, solid tumors | CD20 or PD-L1 mAbs, chemotherapy, IL-2 | NCT04023071, NCT04551885 |
| 158V non-cleavable CD16, CD38 KO, contiguously active IL-15R | Phase I | Multiple Myeloma, AML, monocytic leukemia | Daratumumab or elotuzumab, chemotherapy | NCT04614636, NCT04714372 |
| CD19 CAR, 158V non-cleavable CD16, contiguously active IL-15R | Phase I | B cell lymphoma, CLL | Monotherapy or CD20 mAbs | NCT04245722 |
| CD19 CAR / IL-15 production | Phase I/II | B cell malignancies | Chemotherapy | NCT03056339 |
| BCMA CAR | Phase I/II | Multiple myeloma | Monotherapy | NCT03940833 |
| ROBO1 CAR | Phase I/II | ROBO1 positive tumours | Monotherapy | NCT03940820, NCT03931720 |
| Pancreatic cancer | Monotherapy | NCT03941457 | ||
| PD-L1 CAR, 158V CD16, IL-2 production | Phase II | Various | Chemotherapy, aldoxorubicin HCl, IL-15 superagonist | NCT04390399, NCT03228667, NCT04847466 |
| CD5 CAR, IL-15 production | Phase I/II | R/R Hematological malignancies | Chemotherapy | NCT05110742 |
Abbreviations: AML, BCMA, CLL; ICB, immune checkpoint blockade; MDS, PD-L1, ROBO1, Roundabout homolog 1; R/R, relapsed/refractory